Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT06852846

Clinical Usefulness of a Multi-analyte Immunoassay for Distinguishing Bacterial and Viral Infections in Children

Clinical Usefulness of a Multi-analyte Immunoassay for Distinguishing Bacterial and Viral Infections in a Cohort of Pediatric Febrile Patients

Status
Active Not Recruiting
Phase
N/A
Study type
Interventional
Enrollment
100 (estimated)
Sponsor
Meyer Children's Hospital IRCCS · Academic / Other
Sex
All
Age
3 Months – 18 Years
Healthy volunteers
Not accepted

Summary

Fever can be a clinical manifestation present in pediatric infections, posing a challenge for the doctor who must decide whether or not to prescribe an antibiotic therapy. Routine blood tests can assist the doctor in making a decision, although their response times often do not allow for timely therapeutic decisions. Therefore, there is an increased risk of inappropriate prescribing antibiotics for children with viral infections, which contributes to the increase in antibiotic resistance. There is evidence suggesting the effectiveness of certain biomarkers in distinguishing viral from bacterial forms. Biomarkers of potential interest include tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), interferon gamma-inducible protein of 10 kDa (IP-10), and C-reactive protein. The combination of those tests could distinguish between bacterial and viral infections with 90-94% sensitivity, 88-92.8% specificity, 59-81% positive predictive value and 97-98.8% negative predictive value. This is prospective study using biological samples that aims to evaluate the best diagnostic algorithm for obtaining an early and accurate etiological diagnosis (bacterial infection vs viral infection) of a febrile pediatric patient presenting at the Emergency Department, by comparing the standard algorithm with the diagnostic algorithm integrated with the results of the multi-analytic test.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTBiological sampleBiomarker test for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), interferon gamma-inducible protein of 10 kDa (IP-10), and C-reactive protein

Timeline

Start date
2024-09-23
Primary completion
2025-12-01
Completion
2025-12-01
First posted
2025-02-28
Last updated
2025-02-28

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT06852846. Inclusion in this directory is not an endorsement.